KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Other Non-Current Liabilities (2017 - 2024)

Historic Other Non-Current Liabilities for Bionano Genomics (BNGO) over the last 8 years, with Q2 2024 value amounting to $5.8 million.

  • Bionano Genomics' Other Non-Current Liabilities fell 6037.06% to $5.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $5.8 million, marking a year-over-year decrease of 6037.06%. This contributed to the annual value of $10.9 million for FY2023, which is 1603.7% down from last year.
  • Bionano Genomics' Other Non-Current Liabilities amounted to $5.8 million in Q2 2024, which was down 6037.06% from $10.2 million recorded in Q1 2024.
  • Over the past 5 years, Bionano Genomics' Other Non-Current Liabilities peaked at $14.9 million during Q3 2023, and registered a low of $75000.0 during Q3 2020.
  • Its 5-year average for Other Non-Current Liabilities is $9.2 million, with a median of $10.6 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 20933.33% in 2021, then plummeted by 6037.06% in 2024.
  • Quarter analysis of 5 years shows Bionano Genomics' Other Non-Current Liabilities stood at $75000.0 in 2020, then soared by 11988.0% to $9.1 million in 2021, then surged by 43.06% to $13.0 million in 2022, then fell by 16.04% to $10.9 million in 2023, then plummeted by 46.98% to $5.8 million in 2024.
  • Its Other Non-Current Liabilities stands at $5.8 million for Q2 2024, versus $10.2 million for Q1 2024 and $10.9 million for Q4 2023.